Recent Headlines
Within Biotechnology
smartDOC: Automated Content Management Now with GenAI
smartDOC – Intelligent Content Platform for Knowledge Organizations. Easily manage regulatory content with streamlined process, leverage automation and deliver faster with their enterprise document / content system. - November 11, 2024 - DDi LLC
Synaps Dx Launches Digital Cognitive Screening and Alzheimer’s Testing with BrainCheck and Clarity Health Clinics
Synaps Dx, BrainCheck, and Clarity Health introduce an innovative online Alzheimer's and cognitive health screening tool, accessible from home. Launching in Texas, with nationwide expansion planned, this telehealth solution provides families with a convenient, reliable path to early detection during National Alzheimer’s Disease Awareness Month, reducing the need for in-office visits and empowering proactive cognitive care. - November 04, 2024 - SynapsDx
Rare Disease Foundation on the Road to Gene Therapy Brings Families to Fort Lauderdale from Around the World, November 15-17
The FOXG1 Research Foundation, the parent-led organization that is radically transforming the rare disease drug development landscape, is hosting an international conference in Fort Lauderdale from November 15-17, bringing families from across the globe together to learn about gene therapy advancements for FOXG1 syndrome. A highlight includes a presentation by 20-year-old Abraham Weitzman, who, though non-speaking, shares his lived experience using an innovative communication device. - November 04, 2024 - FOXG1 Research Foundation
GlycoMira Therapeutics Receives Key Patent for First-in-Class Oncology Therapeutic
Key patent covering GlycoMira's lead compound GM-1111 adds to the Company's already strong IP portfolio. - November 04, 2024 - GlycoMira Therapeutics, Inc.
NuvOx Announces Two New Publications
Co-Founders, Dr. Evan Unger and Dr. Jennifer LH Johnson combine efforts to publish 2 journal articles that help explain how the NuvOx drug candidate - NanO2TM works. Artificial Cells, Nanomedicine, and Biotechnology published Dodecafluoropentane emulsion as an oxygen therapeutic, an article that... - October 31, 2024 - NuvOx Therapeutics
EPA Expands TSCA Registration to Full Amphi Biosurfactant Line
Locus FS is now the first US-based company authorized by the EPA to produce biosurfactants at commercial volumes under expanded TSCA registration. This includes the Locus Ingredients division's full line of Amphi sophorolipids, offering formulators USA-made, 100% bio-based alternatives to petrochemical surfactants that can be customized for cleaning, degreasing, and corrosion resistance, while meeting strict regulations. - October 25, 2024 - Locus Performance Ingredients
US EPA Approves Locus FS’ Expanded List of Biosurfactants for the Consumer and Industrial Markets
Locus Fermentation Solutions has become the first and only US-based company authorized by the EPA to produce biosurfactants at commercial volumes under expanded Toxic Substances Control Act (TSCA) registration. This approval positions Locus FS as the leading domestic producer of 100% bio-based glycolipid biosurfactants, providing formulators with scalable, eco-friendly alternatives to chemicals in agriculture, oil & gas, industrial applications, home care, personal care and more. - October 25, 2024 - Locus Fermentation Solutions
Parvus Announces First Human Subject Dosed in a Clinical Trial with PVT201, a First-in-Class Off-the-Shelf Regulatory T-cell (Treg) Inducing pMHC Nanomedicine Therapy
Parvus Therapeutics, a private clinical-stage biopharmaceutical company developing a pipeline of novel treatments for autoimmune disease announced the successful dosing of the first subject in a Phase 1/2, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PVT201 single ascending doses in healthy subjects and primary biliary cholangitis patients. - October 17, 2024 - Parvus Therapeutics U.S., Inc.
Award-Winning Cleantech Startup Joins Cummings Properties' Woburn, MA Innovation Cluster
Active Surfaces, an early-stage solar technology company, expanded from Greentown Labs' cleantech incubator in Somerville, MA to a dedicated R&D facility in Cummings Properties' Woburn, MA innovation cluster. - October 05, 2024 - Cummings Properties
CURE Pharmaceutical Appoints Raymond Watt to Board of Directors
CURE Pharmaceutical, renowned for its innovative sublingual delivery systems, is proud to announce the appointment of Raymond Watt to its Board of Directors. - October 01, 2024 - CURE Pharmaceutical, Inc.
NuvOx Pharma LLC Announces Receipt of Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medical Products
NuvOx Pharma LLC, a wholly owned subsidiary of NuvOx Therapeutics Inc. (together, “NuvOx”) announced that it has received a Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medicinal Products Manufactured outside of EU (in Third Countries) . This... - September 21, 2024 - NuvOx Therapeutics
Superior Rail & Iron Works Named First-Ever Diamond Sponsor for ALS TDI’s White Coat Affair Gala
The ALS Therapy Development Institute (ALS TDI) has announced that Superior Rail & Iron Works, Inc. will be the first-ever Diamond Sponsor for the annual White Coat Affair gala, taking place on October 5, 2024, at the Boston Sheraton. Superior Rail & Iron Works, Inc., which was the gala’s Title Sponsor last year, is continuing its support, helping ALS TDI push forward with critical research to find treatments for ALS. - September 19, 2024 - ALS Therapy Development Institute
Valis Corporation Technology Used in Large Brain Model Project
Using Quantum-Entangled Brain Organoids for Artificial Natural and General Intelligence - September 16, 2024 - Valis Corp
Sama Therapeutics and Quine Biologics Announce Collaboration to Develop Breakthrough Antibody Therapeutics for Neurological Disorders
Sama Therapeutics and Quine Biologics have partnered to develop an innovative therapy for neurological disorders, combining AI-driven platforms and advanced antibody engineering. The collaboration focuses on biologics that precisely target the central nervous system, minimizing side effects. By integrating Sama's generative AI with Quine's antibody design expertise, the project addresses unmet medical needs and advances treatments for conditions like Alzheimer’s and multiple sclerosis. - September 13, 2024 - Quine Biologics, Inc.
Microvascular Therapeutics Announce Completion of Phase 2 Study Enrollment for MVT-100
Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the completion of enrollment in MVT’s Phase 2 program using its microbubble product, MVT-100, for endocardial border delineation. This study, An Ascending Dose Comparison of... - September 13, 2024 - Microvascular Therapeutics, Inc.
Huntington Study Group and HD Genetics Collaborate to Better Serve HD Gene Positive Patients
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce a strategic partnership with HD Genetics to assist patients who have tested positive for Huntington’s disease (HD) learn about and enroll in research studies. There remains a... - September 05, 2024 - Huntington Study Group
ALS Therapy Development Institute Commemorates 25th Anniversary at the Leadership Weekend in October
Taking place from October 3-5, 2024, in the Boston area, ALS TDI’s Leadership Weekend features a series of community-focused events, including an Open House at ALS TDI’s cutting-edge research lab, the ALS TDI Research Summit, and the White Coat Affair gala. - September 03, 2024 - ALS Therapy Development Institute
New Partnership: Luminoso and KAPS Group
We are delighted to announce the partnership agreement between the KAPS Group, a long-time leader in text analytics/semantic AI consulting services for enterprise data-driven solutions, and Luminoso, a leading sentiment analysis company, whose Daylight software, a powerful but easy to use sentiment analysis tool. - August 29, 2024 - KAPS Group
ICH1132 Shows Promise in Early-Stage Tumor Growth Inhibition Studies
New comparative study of ichorbio's anti-PD-1 antibody clone RMP1-14 highlights potential for optimized cancer research protocols. - August 21, 2024 - ichorbio Ltd
Huntington Study Group Announces New CEO
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce that Daniel Claassen, MD, MS, an internationally recognized Huntington’s Disease neurologist and researcher has accepted the role as the organization’s Chief Executive... - August 20, 2024 - Huntington Study Group
Guides Collective Steps in Where Traditional Therapies have Failed with a Concierge Service to Match Seekers with Psychedelic Guides
Guides Collective launches psychedelic concierge service poised to become the "BetterHelp" of the psychedelic space. With over 600+ qualified psychedelic guides in their network, they work with you to find a psychedelic modality catered to a persons specific needs and desired outcome. - August 14, 2024 - Guides Collective
Parvus Therapeutics Announces Leadership Appointments to Support Development from Preclinical Into Clinical
New Positions Enhance Parvus Capability to Execute the Translation of Multiple Drug Candidates into the Clinic. - August 06, 2024 - Parvus Therapeutics U.S., Inc.
Minus K Technology Announces Its Ninth Educational Giveaway of Vibration Isolators to U.S. Colleges and Universities
Minus K Technology announces its Educational Giveaway of Vibrations Isolators to U.S. Colleges and Universities. - August 05, 2024 - Minus K Technology Inc.
Parvus Therapeutics Has Received Orphan Drug Designation for Primary Biliary Cholangitis and Human Research Ethics Committee Approval to Begin Clinical Testing
Parvus Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PVT201 for the treatment of Primary Biliary Cholangitis (PBC) and PVT201 has obtained Australian Human Research Ethics Committee (HREC) approval to initiate a first-in-human... - July 29, 2024 - Parvus Therapeutics U.S., Inc.
Edison Agrosciences Announces $600,000 Seed Financing Round and Addition of Industry Veteran Tom Marsh to Board of Directors
Edison Agrosciences, an industrial biomaterials company developing a sustainable domestic source of natural rubber from sunflowers, today announced the closing of a $600,000 seed financing. - July 26, 2024 - Edison Agrosciences
Leap Years®: Supports Age-Related Cognitive Decline in Dogs and Quality Time Together with Owners Through NAD+ Enrichment
Animal Biosciences Announces Peer-Reviewed Publication of a Clinical Trial to Evaluate the Slowing of Age-Related Signs in Dogs. After five years of development, clinical results are published regarding senior dog aging in a rigorous, placebo-controlled trial performed at a North Carolina State University College of Veterinary Medicine. - July 23, 2024 - Leap Years
U.S. Precision Medicine, Inc. Signs MOU to Deploy microNeb’s VIGIL Series Inhaler Technology to Enhance Absorption of Its New Drug Candidate in IND Process
U.S. Precision Medicine, Inc. (USPM) has signed a Memorandum of Understanding (MOU) to deploy microNeb's advanced inhaler technology to expedite the uptake of its new cancer drug candidate currently in the Investigational New Drug (IND) process. - July 16, 2024 - microNeb, Inc.
MC4R Agonist Drug Candidates Demonstrate Potential to Transform GLP1 Obesity Therapy
Courage Therapeutics announced new evidence of synergy between MC4R agonists and GLP1RA drugs in a paper published in the Journal of Clinical Investigation led by co-founder Dr. Roger Cone. The company has completed a drug discovery campaign to invent a best in class portfolio of MC4R agonists for obesity in order to leverage the synergy. Potential combinations with drugs such as Ozempic and Mounjaro could improve side effects such as nausea and GI discomfort while driving increased weight loss. - July 16, 2024 - Courage Therapeutics
SYNAPS Dx Welcomes Renowned Alzheimer’s Researcher, Dr. Donna Wilcock, to Its Scientific Advisory Board
SYNAPS Dx welcomes Dr. Donna M. Wilcock, a leading Alzheimer's researcher, to its Scientific Advisory Board. Dr. Wilcock's expertise in neuroinflammation and vascular cognitive impairment will support the advancement of the DISCERN™ diagnostic test for Alzheimer's disease. This addition reinforces SYNAPS Dx’s commitment to pioneering accurate, minimally invasive diagnostics for Alzheimer's. For more info, visit SYNAPS Dx's website. - July 15, 2024 - SynapsDx
Huntington Study Group Announces Launch of LEAD-HD Observational Study
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) today announce the release of their newest Patient Reported Outcomes (PRO) study, LEAD-HD. This observational study was developed collaboratively with the University of Rochester Center for Health +... - July 15, 2024 - Huntington Study Group
NuvOx Pharma LLC Announces Authorization of ARDS Trial from Health Canada
NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials. Evan Unger, MD, CEO of NuvOx, said, “Acute Respiratory Distress... - July 12, 2024 - NuvOx Therapeutics
Abel Womack CEO Announces His Retirement and Successor
After 50 years with Abel Womack, John Croce, CEO retires. - June 27, 2024 - Abel Womack Inc
Daicel Arbor Biosciences Launches New myTXTL® Kits to Accelerate Protein Expression
Daicel Arbor Biosciences is excited to announce the release of the next generation of its myTXTL® kits, for cell-free protein expression, designed to simplify and accelerate antibody discovery and protein engineering. These powerful new kits include the myTXTL Pro Kit and the myTXTL Antibody/DS... - June 27, 2024 - Daicel Arbor Biosciences
SYNAPS Dx Announces Expansion to New, State-of-the-Art Facility
SYNAPS Dx has moved to a new, state-of-the-art facility in Rockville, MD, to meet growing demand and enhance patient care. The larger space and advanced infrastructure will support more diagnostic samples and ensure timely, accurate Alzheimer's and dementia diagnoses. Fully qualified for high-complexity clinical lab testing, the facility boosts diagnostic capabilities. The expansion will also advance the DISCERN™ test, a minimally invasive tool distinguishing Alzheimer's from other dementias. - June 26, 2024 - SynapsDx
Cambridge Polymer Group Unveils Restructure to Accelerate Client Innovation through Material Science
Cambridge Polymer Group (CPG) announced a new leadership structure to better support clients in developing innovative products. CPG is creating a new five-person senior management team with deep materials science expertise, which will allow for closer collaboration with clients on complex projects. Dr. Gavin Braithwaite will be the new CEO and Dr. Stephen Spiegelberg will move to the new role of Chief Scientific Officer (CSO). - June 23, 2024 - Cambridge Polymer Group
KIRON.AI Launches Book “NEOBANK Navigating the Future of Banking” by Author and Bank Owner Ronald Ingram
KIRON.AI, a Henderson, Nevada-based AI Health & Wealth company launches “NEOBANK Navigating the Future of Banking,” a groundbreaking book exposing the history and predicting the future of banking from author Ronald Ingram’s perspective as a bank owner, historian, futurist and polymath. The company KIRON.AI employs artificial intelligence (AI) to discover, uncover, develop and deploy protocols, tools and information to enhance human wealth and health preservation and generation. - June 11, 2024 - Kiron.AI
Groundbreaking Study Shows Promise in AAV9 Gene Therapy for FOXG1 Syndrome; Rescue of Brain Structure Abnormalities and Deficits.
New publication shows groundbreaking result in FOXG1 AAV9 gene therapy studies, rescuing structural brain abnormalities caused by the pediatric rare disease, FOXG1 syndrome. This paper summarizing work done by the FOXG1 Research Center, led by Dr. Soo-Kyung Lee, Dr. Jae W. Lee and Dr. Kathrin Meyer (responsible for the SMA gene therapy), shows remarkable rescue of brain abnormalities using AAV9 gene therapy. - June 10, 2024 - FOXG1 Research Foundation
Cayman Chemical Expands Molecular Diagnostic Research Offerings Through Partnership with PCRassays.com
Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com. PCRassays.com offers more than 200 qPCR-based assays for infectious diseases, over 50 of... - June 07, 2024 - Cayman Chemical Company
FlowSense: Affordable Antibiotic Testing to Transform the Honey Industry from Biorex Food Diagnostics
Biorex Food Diagnostics announced today the launch of its cutting-edge FlowSense product line, with the first phase designed specifically for the honey industry. The new FlowSense test products introduce a comprehensive range of antibiotic test panels, providing honey producers with an innovative... - June 07, 2024 - Biorex Food Diagnostics
Limited Opportunity: Enroll in Ales for ALS 2024 Today, Secure Your Spot as Part of a Growing National Movement
Ales for ALS invites brewers to craft distinctive and flavorful beers using a custom hop blend generously donated by Yakima Chief Hops. In exchange, participating brewers pledge to donate $1 for every pint sold, directly contributing to groundbreaking ALS research at the ALS Therapy Development Institute (ALS TDI). - May 04, 2024 - ALS Therapy Development Institute
Revolutionizing Clinical Trials: AnzuBridge Unveils Next-Generation Solutions for Improved Efficacy Evaluations in the Treatment of Rare Disease
AnzuBridge® updates its CDMS to enhance biotech evaluations with advanced video tools, ensuring precise efficacy recording and compliance. It supports scalable trials and features HIPAA-compliant media capture, ePRO for patient engagement, and sophisticated video review capabilities, all integrated with a Learning Management System for efficient trial management. - April 30, 2024 - Anzu
No More Acetone: Thar Process Develops Clean and Green Process to Create Sterile, Fat-Free Lecithin Powder and GMP Quality Oils for Human Consumption
Thar Process, with 34 years of expertise in supercritical fluid extraction, has developed a sustainable way to produce de-fatted lecithin powder that has less oil and longer shelf-life stability. The new process is semi-continuous and sustainable because it utilizes upcycled CO2 from waste sources instead of using toxic acetone which is the industry standard. - April 26, 2024 - Thar Process, LLC
Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings
Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union. This... - April 25, 2024 - ALPCO
Mirror Biologics, Inc. Appoints Elizabeth Czerepak as Chief Financial Officer and VP Corporate Development
Mirror Biologics, Inc., a clinical stage biopharmaceutical company announces the appointment of Elizabeth Adkins Czerepak as Chief Financial Officer (CFO) and Vice President of Corporate Development effective April 15, 2024. Ms. Czerepak has served as CFO of several biotechnology companies over... - April 18, 2024 - Mirror Biologics, Inc.
Huntington Study Group Launches Project AWARE 2.0 Observational Study
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce the launch of Project AWARE 2.0, an observational study developed in collaboration with Roche Products Limited and Genentech to understand and improve Awareness, Willingness, and... - April 10, 2024 - Huntington Study Group
Minus K Congratulates to the Winners of Their 2023/2024 Educational Giveaway
Minus K congratulates the four winners of the Minus K's 2023/2024 Educational Giveaway. Over $75,000 of new passive mechanical hub hertz vibration isolators have been granted to universities and colleges in the U.S. over the last ten years. - April 10, 2024 - Minus K Technology Inc.
FuseBio Presents New Data at AACR: Targeting a Functionally-Selective IL-18 (F-18) to PD-1: A Next Generation Checkpoint Inhibitor with Enhanced Anti-Tumor Activity
FuseBio's unique attenuation mechanism renders IL-18, a functionally selective IL-18, resistant to IL-18BP and 1 million percent less active in circulation and yet still retain nearly full activity when targeted to PD-1+/IL-18R+ cells, the key functional immune cells in tumors. It is designed to retain full activity of PD-1 checkpoint blockade and simultaneously deliver a functionally selective IL-18 (F-18) to preserve and enhance the anti-tumor activity of immune cells. - April 09, 2024 - Fuse Biotherapeutics
Ngram Expands AI Dataset Offerings with Descriptive Question Answering for Healthcare
New open-source medchat-qa-descriptive dataset enables AI models to provide comprehensive answers to complex medical queries. - March 22, 2024 - ngram Inc.
Parvus Announces Collaboration with AbbVie to Develop IBD Therapies Based on the Parvus Navacim Platform Technology
The collaboration will combine AbbVie’s expertise in Immunology with Parvus’ innovative Navacim™ regulatory T cells (Treg) immune tolerization platform technology to develop therapies for Inflammatory Bowel Disease Parvus Therapeutics announced today that it has entered into an... - March 20, 2024 - Parvus Therapeutics U.S., Inc.
MENADNA and ProPhase Labs' (NASDAQ: PRPH) Wholly-Owned Subsidiary, Nebula Genomics, Announce Strategic Partnership to Enhance Genomic Testing in Jordan, Oman and Iraq
MENADNA Inc., has entered into an exclusive partnership with ProPhase Labs' subsidiary, Nebula Genomics, aiming to advance genomic testing in Jordan, Oman, and Iraq. This collaboration will leverage Nebula Genomics' advanced sequencing technologies and MENADNA's bioinformatics capabilities to improve the quality and relevance of genomic data in these historically underserved regions. - March 18, 2024 - MENADNA